Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington’s Disease and Amyotrophic Lateral Sclerosis (HD & ALS)

Emerging Therapeutics for Neurodegenerative Diseases Part II: Huntington’s Disease and Amyotrophic Lateral Sclerosis (HD & ALS)

Publication date: Oct 08, 2019

Read the full report: present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.

Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies. Some Multifactorial Conditions to WatchAbnormal protein dynamics Defective protein degradation and aggregationOxidative stress Free radical formation Impaired bioenergetics Mitochondrial dysfunctionExposure to toxic metals and pesticidesOthersCoverage of Neurodegenerative Diseases TechnologiesThis research service, ‘Emerging Therapeutics for Neurodegenerative Diseases’, focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.

The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitivenessThe study covers the following topics:Technology roadmap, trends, capabilities, and applications targetedStakeholder activities, influence, industry initiatives, investment environment, and funding supportRegional and global regulation landscape and standardization approaches for tackling challengesTechnology benchmarking for smart decisionsAn appendix is included, comprising lists of major industry influencers found in the field.

Concepts Keywords
Aging Neuroscience
ALS Branches of biology
Alzheimer Senescence
Amyotrophic Lateral Sclerosis Nervous system
Benchmarking Organ systems
Bioenergetics Biopharmaceutical biotechnology
Biomarkers Neurodegenerative diseases
Biopharmaceutical Neurodegenerative disorders
Biotechnology Overall neurodegenerative diseases
Clare Therapeutics Neurodegenerative Diseases
Cognitive Neurodegeneration
ComUS Degenerative disease
Etiology Amyotrophic lateral sclerosis
Free Radical Neuroprotection
Huntington Topics Technology
Inflammation Biotechnology
Misfolding
Mitochondrial
Mutant
Nerve
Nervous System
Neurodegeneration
Neurodegenerative
Neurodegenerative Diseases
Neurodegenerative Disorders
Neurons
Oxidative Stress
Parkinson
Stress
Sustainability

Semantics

Type Source Name
disease DOID neurodegenerative disease
disease MESH Amyotrophic Lateral Sclerosis
disease MESH Neurodegenerative Diseases
pathway BSID Neurodegenerative Diseases
disease MESH communities
disease MESH causes of death
disease MESH inflammation
disease MESH oxidative stress
pathway BSID Oxidative Stress
disease MESH aging
disease DOID face
gene UNIPROT ELOVL6
gene UNIPROT FANCE
disease MESH diagnosis
pathway BSID Aging
disease DOID Amyotrophic Lateral Sclerosis
gene UNIPROT IGFALS
gene UNIPROT PLXNA2
drug DRUGBANK Spinosad
gene UNIPROT ITLN1

Similar

Leave a Comment

Your email address will not be published. Required fields are marked *